Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens - Wikidata - thesis-toulmin - TriplyDB

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

http://www.wikidata.org/entity/Q36500269

about

Schistosomiasis vaccines: where do we stand?Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models.Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract.Optimisation of a murine splenocyte mycobacterial growth inhibition assay using virulent Mycobacterium tuberculosis.Alternatives to mineral oil adjuvants in vaccines against Aeromonas salmonicida subsp. salmonicida in rainbow trout offer reductions in adverse effects Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance.Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice Modulation of Primary Immune Response by Different Vaccine Adjuvants.Vaccine efficacy and T helper cell differentiation change with aging.Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung Distinct Antigen Delivery Systems Induce Dendritic Cells' Divergent Transcriptional Response: New Insights from a Comparative and Reproducible Computational Analysis.Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses.Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development.Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling.Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection.Tuberculosis vaccines - perspectives from the NIH/NIAID Mycobacteria vaccine testing program.Structure-function relationships of protein-lipopeptide complexes and influence on immunogenicity.Inflammatory responses to influenza vaccination at the extremes of age.The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.Sensing Lipids with Mincle: Structure and Function.Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model.Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant.T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties.Progress and challenges in TB vaccine development.Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines.Adjuvant-dependent enhancement of HIV Env-specific antibody responses in infant rhesus macaques Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant Adjuvanted influenza vaccines Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making

P2860

Q28066042-9FD83196-B544-4D57-AC4B-F1EE9787C143 Q33614952-85CE1BB9-6724-41E3-AAB2-83F89CD1DC15 Q33694896-88C5B379-AD0E-4443-B0CC-D9520416BC3F Q33767388-7C558D01-55D9-469D-8BF2-8E70978F5FE7 Q33918586-694DB667-81FF-451F-AC25-2AFCAEF02166 Q36239573-FD0CD491-8FFF-45DD-A70A-F89AFF2D7989 Q36845154-AB3E2AF3-72E3-4310-850F-DB7C55E9F531 Q36974221-DD70A256-40C6-48AE-B8EE-32A217E79614 Q37140167-AF27CFA4-74E7-498E-913E-D42000FBD071 Q37342800-CE6A9603-BA43-4A53-BDFF-308DF0971203 Q37376099-56B4CAE2-62A8-49DB-BDE5-E17D1F902C48 Q37497620-628E5218-1D5B-419E-BAC4-0C46A33322ED Q37666257-80048D10-6492-47AD-88F2-DE570F126376 Q37729017-F23A99F7-6E68-4C42-B423-D60A7413C842 Q37834166-92FA209C-287D-4FF7-855A-7174136228F9 Q37837221-C84A665B-0968-41B0-BB99-5E1964F895B6 Q39197667-65E84943-C1F7-4277-A30D-A6AA14DC4EA8 Q40064119-F1E57A9E-0AF2-4006-9A09-5AF1B6B113A3 Q40076470-90AE2A84-B953-4A4C-BB1F-AB7B47533A10 Q40089069-493BFF29-9D88-4604-9514-C8EA3EC2A69D Q40116835-796EEF45-224B-4EA3-9F82-8259B174516C Q40130682-41123D35-FFCA-491E-8BAE-158D577F7EF1 Q40259120-ADEC578F-882A-4A30-BF93-9ADCF1C49108 Q41836016-81258D23-8F29-4B1D-9F43-34B760B4E964 Q46243321-67C50904-F618-48A3-8287-BD24E1288E0A Q47221323-81FDAA4B-9A19-446A-A7E3-C1D716C0496A Q47550128-911587FA-3A2B-4E80-9F3B-CDCA9F413AA4 Q49713237-F4B166E1-B78D-404B-876C-9265853A6E63 Q52641498-0931FAF6-1801-4215-B149-F5A01D1288E2 Q52655234-247A5EBA-BC6D-467A-9788-9AB5E7DB6F38 Q55001017-1C30A806-A9FA-4E73-990A-289CB28846F6 Q55165676-A79E07E1-616D-4B07-8D55-4BE4F2586F4B Q55215825-74677AE8-993E-4437-8276-D705727D4F98 Q55669579-6C6D4E81-A707-457E-AD97-CBE339DBB9BD Q56345991-2D36738E-F423-425F-8EFC-22811E1F65C8 Q57070723-FA594FF0-6B9D-49E6-A676-822837800877 Q57094841-1087D470-39E3-4D3E-86D0-26D58C8E47FF Q58375482-8989D004-8AF8-42A9-9EC4-D590D5AB3198

P2860

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

http://www.wikidata.org/entity/Q36500269

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Different human vaccine adjuva ...... ailored to different pathogens

@ast

Different human vaccine adjuva ...... ailored to different pathogens

@en

type

label

Different human vaccine adjuva ...... ailored to different pathogens

@ast

Different human vaccine adjuva ...... ailored to different pathogens

@en

prefLabel

Different human vaccine adjuva ...... ailored to different pathogens

@ast

Different human vaccine adjuva ...... ailored to different pathogens

@en

P1433

Q36500269-D5570EFF-25B1-43EA-AEDD-201B9D22DAF2

P1476

Q36500269-086D5BCF-1F53-417C-963F-3588B2954588

P2093

Q36500269-12863066-2E85-4297-8423-204BD110F2C0

Q36500269-1B827ACE-31F7-414C-B61E-313D5A72B877

Q36500269-1FF31E72-B4DD-4C33-8B24-CF370695FABE

Q36500269-22C7CCCC-B84F-415D-834A-3D1DF78044C0

Q36500269-30AB8AD2-14D1-4C15-B22B-5AD0A15E77C9

Q36500269-4EB55FBA-CC63-447D-AE52-B2002979C71C

Q36500269-6F0A78E7-6CE3-47DC-A0A2-6EE4268F8CAE

Q36500269-7CFF5974-2542-43B6-8AAF-F9D5567D714B

Q36500269-AA934918-19BB-4D89-B326-EA2C07AFFA9D

Q36500269-BBED71B5-8CF7-460C-8C26-026B335F6496

P2860

Q36500269-02998D8A-47C4-46C4-B13E-27E46DE97D58

Q36500269-05278366-468D-440B-9D1C-2188951633BA

Q36500269-0775C368-5088-4E3F-9C67-19ABC20553E8

Q36500269-08B0C964-B9A7-4919-8FB1-78720DF5B6E0

Q36500269-0A3C79C9-9278-45CF-AF9C-4789CD5BA274

Q36500269-0E10A4AE-903B-4779-A2AD-FC33C1487C4F

Q36500269-1202F5CF-C0B5-445E-A016-6C3BA82C5284

Q36500269-12B720AB-B5F2-4F80-A3E8-4BD025E89536

Q36500269-12D55E72-1A63-4F08-B62F-C1D4BA957A38

Q36500269-1375A3B9-0AAF-4A1D-9AEC-99C0C50A3660

P2888

Q36500269-F8F697FE-CF6C-43AE-AE7A-861C2DF2F939

P304

Q36500269-87E87636-0903-4D56-BF6C-5DCE73F1534E

P31

Q36500269-354FD229-5110-4E71-9F54-5A8E8723C7CF

P356

Q36500269-C99E49FB-E103-4CB9-A7CA-0B6E274D0646

P407

Q36500269-8E951586-BD1F-473E-B329-6D3ED25DAD55

P478

Q36500269-1FDA69A4-1546-4A09-A0EF-587E2D602D85

P50

Q36500269-33E308E9-AED0-4B11-B9D6-4A03DCB43614

Q36500269-4EDDF765-BEC5-4B70-AAF3-C0B92B0809F1

Q36500269-6E6EBBA6-E601-4399-AD01-DC30FEA58CB6

Q36500269-E5248A2A-980E-4E29-96BF-9CFB9A101BF0

P577

Q36500269-33908C7F-7ADD-4641-B622-255CFA1F1496

P5875

Q36500269-355DD09F-C2D8-44DF-98C8-8B0D3E72621C

P698

Q36500269-21C5F8A5-F3C5-4F6F-B45E-5FB02B4AB731

P921

Q36500269-FDF7D698-2FBE-4250-A2A8-CA8B18872EC5

P932

Q36500269-E1ADF27C-98BF-4EAF-8150-D8C8EED5E7CD

P356

P1433

Scientific Reports

P1476

Different human vaccine adjuva ...... ailored to different pathogens

@en

P2093

Alessandra Bonci

http://www.w3.org/2001/XMLSchema#string

Ali M Harandi

http://www.w3.org/2001/XMLSchema#string

Andreas Meinke

http://www.w3.org/2001/XMLSchema#string

Anja Olsen

http://www.w3.org/2001/XMLSchema#string

Cecilia Buonsanti

http://www.w3.org/2001/XMLSchema#string

Christopher B Fox

http://www.w3.org/2001/XMLSchema#string

Daniele Casini

http://www.w3.org/2001/XMLSchema#string

Else Marie Agger

http://www.w3.org/2001/XMLSchema#string

Ennio De Gregorio

http://www.w3.org/2001/XMLSchema#string

Frank Follmann

http://www.w3.org/2001/XMLSchema#string

P2860

CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

T-cell quality in memory and protection: implications for vaccine design

Cellular immune correlates of protection against symptomatic pandemic influenza.

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies

The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

P2888

P304

19570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP19570

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

291420720

http://www.w3.org/2001/XMLSchema#string

P698

26791076

http://www.w3.org/2001/XMLSchema#string

P921

P932

4726129

http://www.w3.org/2001/XMLSchema#string